Marc Ramis Castelltort

Marc Ramis Castelltort has a diverse work experience in the biotech and pharma industry. Marc co-founded and serves as a Partner at Chasing Science since March 2017. Additionally, they are also an Advisory Board member at Deep Science Ventures starting from November 2021. In 2023, they joined Ship2B Ventures as a Venture Partner and co-founded Nanobots Therapeutics. Marc also serves as an Interim Management and Board Observer at DIVE Medical and as a Board Member at Oniria Therapeutics. Marc co-founded Ninevah Therapeutics in 2019 and holds the position of Co-Founder and Board Member. Marc is also an Interim Management and Board Member at Aptadel Therapeutics. Furthermore, Marc is a Co-Founder and Board Member at Gate2Brain, with a focus on improving drug delivery for pediatric diseases. Marc is also a Board Member at CEBIOTEX, which is dedicated to developing tumor control solutions.

Marc Ramis Castelltort completed their education in a chronological order. Marc first attended Universitat Ramon Llull from 1995 to 2000, where they obtained a Bachelor of Science degree in Chemistry. Following this, from 2000 to 2001, they pursued a Master of Science degree in Chemical Engineering at Boston College. Upon completion of their master's degree, they then enrolled at the University of Oxford in 2002 and graduated in 2006 with a Doctor of Philosophy (D.Phil) in Biochemistry and Medical Chemistry. Lastly, in 2010 and 2011, they attended Harvard Business School for Executive Education, specializing in PLD (Program for Leadership Development).